Published • loading... • Updated
CVS Health: Q2 Earnings Snapshot
The Phase 1b/2b study will test whether the drug pair can overcome KRAS G12C resistance and improve outcomes for advanced lung cancer patients.
- On Tuesday, August 4, 2026, Amplia Therapeutics and Eli Lilly & Company signed a Clinical Trial Collaboration and Supply Agreement to evaluate narmafotinib combined with olomorasib for non-small cell lung cancer .
- Research indicates that FAK activation drives resistance to KRAS G12C inhibitors, often limiting the duration of patient benefits from current treatments. The partnership addresses this critical resistance mechanism.
- The Phase 1b/2b clinical trial will assess safety and efficacy of combining narmafotinib with olomorasib as a second-line treatment for advanced-stage NSCLC patients. Amplia will conduct the study at sites across Australia and the United States.
- "This collaboration is an exciting new stage in the clinical progression of narmafotinib," Amplia CEO Dr. Chris Burns said, adding that combining FAK and KRAS inhibition could lead to improved outcomes.
- Targeting a market valued at about $31 billion and forecast to grow to more than $60 billion by 2033, the trial expands Amplia's clinical reach into NSCLC across Australia and the United States.
Insights by Ground AI
17 Articles
17 Articles
Coverage Details
Total News Sources17
Leaning Left4Leaning Right2Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 31%
C 54%
15%
Factuality
To view factuality data please Upgrade to Premium
